2023-06-26 17:16:00
Novo Nordisk Pharmaceuticals plans to apply to the US Food and Drug Administration for approval to produce these pills later this year.
Washington – Associated Press
Posted on: June 26, 2023: 09:16 PM GST Last updated: June 26, 2023: 09:49 PM GST
What if you might get rid of obesity easily by swallowing a pill? This idea, or rather this dream that has long been dreamed of by more than 40% of American citizens who suffer from obesity, may soon become a reality.
Taking high doses of the drug “Wigofy”, which is taken as an oral pill, may be just as effective as a common injection when it comes to losing pounds of body weight and improving general health, according to the final results of two studies published Sunday night.
These powerful pills also seem to work for people with diabetes who are struggling to lose weight.
The drug company, Novo Nordisk, intends to submit an application to the US Food and Drug Administration for approval to produce these pills later this year.
In this context, said Dr. Daniel Bicesen, chief of endocrinology at Denver Health General Hospital, who treats patients with obesity but was not involved in the new research: “If you ask a random question to people … Would you prefer to take a pill or an injection? You will find that The overwhelming majority prefer to take pills.
That answer comes with the assumption that both ways of taking medication are effective, available, and affordable, Bissesen added. “These are the most important factors for the population.”
It is noteworthy that there are other weight loss pills on the market, but they did not achieve the significant reduction in weight achieved by the drugs to which “Wegovi” was added.
Dr. Katherine Saunders, associate professor of internal medicine at Weill Cornell Health and co-founder of bariatric medical company IntelliHealth, said obese people would be “happy” if they had an equally effective oral option.
Novo Nordisk already sells the approved diabetes drug Repelsis, which is an oral pill version of smagglutide, the same drug used in diabetes drugs Ozambik and Wegovi.
Uzbek real estate
The drug comes in doses of up to 14 milligrams. However, the results of two standard trials were released during the annual meeting of the American Diabetes Association on the effect of oral doses of “smaglutide” at a concentration of 25 milligrams and 50 milligrams on reducing weight, improving blood sugar and other health indicators.
A 16-month study of nearly 1,600 overweight or obese people who were already receiving treatment for type 2 diabetes concluded that higher doses of the daily pill lowered blood sugar better than standard doses of Repelsys. From an average adult weight of 96kg, the higher doses resulted in a loss of between 6.8kg and 9.07kg, compared to around 4.5kg for the lower dose.
Another 16-month study of more than 660 obese or overweight adults with at least one obesity-related disease — but not diabetes — concluded that taking the 50-milligram pill daily helped people lose regarding 15 percent of their weight. Their average body weight, or regarding 18.85 kilograms, compared to regarding 2,720 kilograms with a placebo. The study authors said this was “significantly consistent” with the weight loss resulting from weekly dosing of the highest dose of Wiggoi.
However, the drug had side effects. About 80% of participants who received any dose of semaglutide by mouth experienced symptoms such as mild to moderate gastrointestinal problems, such as nausea, constipation and diarrhea. In the trial of obesity drug treatment with a concentration of 50 milligrams, there was evidence of higher rates of benign tumors among people who took the drug compared to the placebo. Moreover, regarding 13% of those who took the drug felt a “change in skin texture,” such as tingling or increased sensitivity.
Read also
1687848823
#injections. #daily #tablet #Wegovi #treat #obesity